

IFW

A circular black and white stamp. The text "OIPE" is at the top, "LAP97" is at the top right, "FEB 28 2007" is in the center, and "PATENT & TRADEMARK OFFICE" is at the bottom.

Group Art Unit: 1614

Attorney
Docket: 30724

Attorney
Docket: 30724

22

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.


This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Mark D. Moynihan

Martin D. Moynihan
Registration No. 40,338

Dated: February 25, 2007



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/555,664
Filing Date	November 4, 2005
First Named Inventor	Peter ASSAF et al
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	30724

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-2005/0137191	06-23-2005	Thatcher et al.	
	2	US-6,310,052	10-30-2001	Thatcher et al.	
	3	US-5,883,122	03-16-1999	Thatcher et al.	
	4	US-5,807,847	09-15-1998	Thatcher et al.	
	5	US-2002/0177622	11-28-2002	Thatcher et al.	
	6	US-6,916,835	07-12-2005	Thatcher et al.	
	7	US-09/473,713	12-29-1999	Thatcher et al.	
	8	US-5,404,871	04-11-1995	Goodman et al.	
	9	US-5,542,410	06-6-1996	Goodman et al.	
	10	US-5,874,063	02-23-1999	Briggner et al.	
	11	US-5,983,956	11-16-1999	Trofast	
	12	US-6,221,398	04-24-2001	Jakupovic et al.	
	13	US-6,268,533	07-31-2001	Gao et al.	
	14	US-6,566,324	05-20-2003	Nadel et al.	
	15	US-6,571,790	03-3-2003	Weinstein	
	16	US-6,637,430	10-28-2003	Voges et al	
	17	US-6,652,323	11-25-2003	Yanda	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
	18	PCT WO 01/49275	07-12-2001	Thatcher et al.		
	19	PCT WO 03/086282	10-23-2003	Fang et al.		
	20	PCT WO 00/30614	02-2-2000	Bisrat et al.		
	21	PCT WO 99/55319	04-4-1999	Cooper		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project (08-03), no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/555,664
				Filing Date	November 4, 2005
				First Named Inventor	Peter ASSAF et al
				Group Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	Of	2	Attorney Docket Number	30724
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	22	Kumar et al. "Design, Synthesis, and Evaluation of α -Ketoheterocycles as Class C β -Lactamase Inhibitors", Bioorganic & Medicinal Chemistry, 9: 2035-2044, 2001.			
	23	Cavicchi et al. "Inhibition of Inducible Nitric Oxide Synthase in the Human Intestinal Epithelial Cell Line, DLD-1, by the Inducers of Heme Oxygenase 1, Bismuth Salts, Heme, and Nitric Oxide Donors", GUT, 47(6): 771-778, 2000. Abstract.			
	24	Salas et al. "Nitric Oxide Supplementation Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice", Laboratory Investigation, 82(5): 597-607, 2002. Abstract, P.602, Col.1, Lines 3-19.			
	25	Ueda et al. "Structure-Activity Relationships of 2-Aminothiazole Derivatives as Inducible Nitric Oxide Synthase Inhibitor", Chemical & Pharmaceutical Bulletin, 52(5): 634-637, 2004. Abstract, P.634, Col.2, Last Line - P.635, Col.1, Line 2, Table 2, Expls. 5a, 5b, 7, P.636, Col.1, Lines 17-18, 25-39.			
	26	Münzel et al. "Evidence for Enhanced Vascular Superoxide Anion Production", The Journal of Clinical Investigation, 95: 187-194, 1995.			
	27	Chung et al. Identification of the Subcellular Site for Nitroglycerin Metabolism to Nitric Oxide in Bovine Coronary Smooth Muscle Cells", The Journal of Pharmacology and Experimental Therapeutics, 253(2): 614-619, 1990.			
	28	McGuire et al. "Inhibition of NADPH-Cytochrome P450 Reductase and Glyceryl Trinitrate Biotransformation by Diphenyleneodonium Sulfate", Biochemical Pharmacology, 56: 881-893, 1998.			
	29	Needleman et al. "Sulphydryl Requirement for Relaxation of Vascular Smooth Muscle", The Journal of Pharmacology and Experimental Therapeutics, 187(2): 324-331, 1973.			
	30	Bueb et al. "Natural Polyamines Stimulate G-Proteins", Biochemical Journal, 282: 545-550, 1992.			
	31	Loscalzo "N-Acetylcysteine Potentiates Inhibition of Platelet Aggregation by Nitroglycerin", Journal of Clinical Investigation, 76: 703-708, 1985.			
	32	Kurz et al. "Nitroglycerin Metabolism in Vascular Tissue: Role of Glutathione S-Transferases and Relationship Between NO and NO ₂ -Formation", Biochemical Journal, 292: 545-550, 1993.			

Signature		Considered	
-----------	--	------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.